Navigation Links
Response Genetics, Inc. to Release Second Quarter Financial Results and Host Conference Call on August 14, 2012
Date:8/7/2012

LOS ANGELES, Aug. 7, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce its second quarter financial results and give an operational update in a press release to be issued before the market opens on Tuesday, August 14, 2012. The company will host a conference call that same day at 10:00 a.m. EDT to discuss its financial results.

Conference Call DetailsTo access the conference call by phone on August 14 at 10:00 a.m. EDT, dial (800) 537-0745 or (253) 237-1142 for international participants.  A telephone replay will be available beginning approximately two hours after the call through August 21, 2012 and may be accessed by dialing (855) 859-2056 or (404) 537-3406.  The conference passcode for both the live call and replay is 18367261.

To access the live and archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.responsegenetics.com.  It is advised that participants connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.

About Response Genetics, Inc.Response Genetics Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. The Company's principal customers include oncologists, pathologists and hospitals. In addition to diagnostic testing services, the Company generates revenue from the sale of its analytical testing services of clinical trial specimens to the pharmaceutical industry.  The Company's headquarters is located in Los Angeles, California. For additional information, please visit www.responsegenetics.com.

Forward-Looking Statement NoticeExcept for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into new areas such as companion diagnostics, to continue to execute on its business strategy and operations, to continue to  analyze cancer samples, and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.  

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law. Investor Relations Contact:

Media Relations Contact:Peter Rahmer

Barry SudbeckTrout Group

Fleishman-Hillard646-378-2973

415-318-4261


'/>"/>
SOURCE Response Genetics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
2. Market response to Kallo technology
3. Response to U.S. Supreme Courts Healthcare Decision by Michael Zamagias, Chairman, TeleTracking Technologies
4. Masimo Deploys Kinaxis RapidResponse for Global Demand and Supply Balancing
5. FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
6. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
7. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
8. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
9. Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets
10. Alexza Receives Complete Response Letter for Adasuve™ NDA
11. Press Ganey Releases Enhanced Improvement Portal with Customized Performance Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... Mass. , May 24, 2016  NxStage Medical, ... technology company focused on advancing renal care, today announced ... plans to participate in the following schedule of investor ... be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, June ...
(Date:5/24/2016)... KONG , May 24, 2016 ... , the world , s first ... AV fistula intervention   OrbusNeich, a global ... has expanded its portfolio to include products to treat ... are the company,s first entry devices for lower limb ...
Breaking Medicine Technology:
(Date:5/26/2016)... St. Louis, Missouri (PRWEB) , ... May 26, ... ... optimal cost, quality and clinical outcomes, hosted members and suppliers for its inaugural ... with a focus on their mission of elevating the operational health of America’s ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... has a significant negative impact on long-term patient survival, reports a team of ... published online this week in the Journal of Thoracic and Cardiovascular Surgery, provide ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute ... six-week smoking cessation class starting June 6 at their clinic in downtown Tampa. The ... , Additionally, the Lung Institute has created a free downloadable 4 Week Smoking ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, ... his wonderful accolades and stellar patient reviews, Dr. Batelli continues to be recognized ... Eugene Batelli is a highly trained Podiatric Surgeon who specializes in treating athletes ...
Breaking Medicine News(10 mins):